Henlius（2696.HK）
2020 Annual Results Investor Presentation

March 2021

Disclaimer

- Henlius, the representor or the provider does not make any warranties, statements or representations, express or implied, on the content of this document (the content of this document may also include forward-looking statements), including but not limited to statements about the timeliness, universality and accuracy of the content for any specific purpose or with regard to the correctness of the information obtained by using the content of this document. If any conduct or consequence is caused by any mistake, omission or incorrectness of the relevant content, Henlius, the representor or the provider shall not be liable.

- All rights, including copyrights, of this document and the content contained herein shall be exclusively owned by Henlius, among which the relevant words, patterns and logos relating to “Henlius” and “复宏汉霖” are the names, trademarks and logos legally owned by Henlius. No third-party could use them by any means, including reproduction, without written consent from Henlius.

- The content of this document does not include and shall not be deemed as any advice (including but not limited to medical advice and investment advice). You shall be liable for any decision made by yourself based on the content of this document.

1

Company Overview and Strategy

Company Mission & Key Milestones

Mission:
Affordable Innovation
Reliable Quality

Products Commercially Launched	3
Products under NDA Review	2
Products/Combo Therapies under Clinical Development	10/8
Current Commercial Capacity	20,000L
Expected Total Capacity in 3 years	80,000L

2020.12	HLX01 (rituximab) for Rheumatoid Arthritis NDA Accepted by NMPA
2020.12	HLX03 (adalimumab, 汉达远®) Launched
2020.09	HLX04 (bevacizumab, 汉贝泰®) NDA Accepted by NMPA
2020.08	HLX02 (trastuzumab, 汉曲优®) Approved in China
2020.07	HLX02 (trastuzumab, Zercepac®) Approved in the EU
2019.05	HLX01 (rituximab, 汉利康®) Launched
2015.12	GMP Manufacturing Facility in Operation
2011.12	First NMPA IND Filed (HLX01, rituximab)
2010.02	Shanghai Henlius Biotech Inc. Founded (co-founded by Fosun Pharma and scientist team headed by Dr. Scott Liu and Dr. Weidong Jiang)

Management Team： More Executives Joined Henlius with Global Background in Recent Years

Wenjie Zhang

- Joined Henlius in Mar 2019
- 25 years of commercial operation experience in pharmaceutical industry
- Former business head, business vice president and general manager at Bayer China, Roche China and Amgen China
- MBA in Yale University and bachelor degree of microbiology in Shandong University

AMGEN · Roche · BAYER

Executive Director

Chief Executive Officer & President

Xinjun Guo
Board Secretary, Head of Government Affairs and Public Relations

SBIA

Wei Huang
Chief Operation Officer
Head of Manufacturing & Engineering
Joined Henlius in Dec. 2019

newa TECHNOLOGY INC. · REG FLUOR · Baxter

Jason Zhu
Chief Medical Officer
Joined Henlius in Jan. 2021

PPC 佳生 · IQVIA · Omnicare

Simon Hsu
Chief Technology Officer
Head of Technical Operations & CMC
Joined Henlius in Dec. 2019

pieris · Takeda · AstraZeneca · ALEXION

Cecie Jiang
Head of Quality Management

twiB · Boehringer Ingelheim · Aphena Pharma Solutions

Wenfeng Xu
Senior Vice President of Research and Development

Genentech A Member of the Roche Group · novo nordisk · ZYMOGENETICS A Bristol-Myers Squibb Company

Ningshu Liu
Head of Translational Medicine
Joined Henlius in Aug. 2020

BAYER

Xinlei Li
Chief Financial Officer
Joined Henlius in Dec. 2020

FOSUN PHARMA 复星医药

Ping Cao
Head of Business Development

ABZENA · FERRO · Bristol-Myers Squibb

Kurt Yu
Head of Marketing and Commercial Operation
Joined Henlius in Aug. 2019

Roche · AMGEN · gsk

Wallis Zeng
Head of Sales
Joined Henlius in Sep. 2019

Roche · MERCK · 恒大健康 EVERGRANDE HEALTH · AstraZeneca

Henlius

Company Size: the Number of Employees Rapidly Grew with Commercial Team Expanding Quickly





R&D	Clinical	Manufacturing	Quality	Commercial	Administrative
351	231	437	256	395	203

Note: as of Dec 31, 2020

Henlius

Company Strategy：Maximize Biosimilar Commercial Value, Accelerate Diversified Innovation with Full Speed

Strategic Goals

Overall	While maximizing biosimilar commercial value, rely on self innovative R&D capability complemented with external collaboration and license-in, accelerate innovation with full speed
R&D	Synergize China and US R&D centers, strengthen translational medicine capability, advance differentiated innovation
Manufacturing	Under the premise of guaranteeing "Henlius Quality", further improve manufacturing capability, optimize manufacturing technology, create competitive economies of scale
Commercialization	Build first-class commercial team in the industry through innovative marketing, access and commercialization strategies, and highly-efficient sales execution capability

Stage 1：Biosimilar

Build comprehensive commercial capability through forging leading position in biosimilar

- Accelerate R&D, registration and approval: strive to become first-in-class or tier-1 to launch
- Further expand leading advantages in manufacturing technology, cost and scale
- Rely on our own capability and leverage external cooperation to maximize commercial value of products

Stage 2：Diversified Innovation

Accelerate transformation towards diversified innovation including mAb, bispecific, ADC, etc. based on antibody technology

- Mainly rely on internal R&D: strengthen R&D innovation capability, improve innovation efficiency
- Establish executable and measurable R&D strategy
- License-in new products and new technologies through BD to effectively complement our own pipeline
- Build strong R&D team and capability

Globalization Strategy

- Commercialize late-stage assets including biosimilars and PD-1 through partnership in the early stage
- Develop mature markets and emerging markets simultaneously
- Actively advance globalization of selected early-stage innovative products

Henlius

Company Highlights: Biosimilar Lays Solid Foundation, Accelerate Development of Bio-Innovative Drugs

Biosimilar Lays Solid Foundation	PD-1 (HLX 10, serplulimab) Entering Harvest Time, Focus on Differentiation and Combo Advantages	Accelerate Innovation through Internal R&D + BD
• Three blockbuster biosimilars have strong competitive edges – 汉利康®（rituximab）、汉曲优®（trastuzumab）、汉达远®（adalimumab）expected to become market leaders through first-mover and sales advantages • Manufacturing advantage generates cost advantage – rapidly increasing capacity and application of advanced technology, continuously decrease manufacturing cost • China & EU-certified global quality standards – endorse “Henlius Quality”, lay solid foundation for overseas market expansion • Actively prepare for volume-based procurement – no major impact expected on HLX01 and HLX02, active preparation for HLX03 and HLX04 through cost advantage	• PD-1 entering harvest time – gradually file NDA for multiple indications such as MSI-H and sq-NSCLC starting from 2021 • Combo advantage – HLX10+HLX04 (PD-1+VEGF) for ns-NSCLC, HCC; HLX10+HLX07 (PD-1+EGFR) for SCCHN • Differentiation advantage –Neo-adjuvant GC, MSI-H, etc. • Overseas sales of innovative drugs – PD-1’s multiple global multi-center clinical trials (sq-NSCLC, SCLC, etc.) to prepare for overseas sales	• Optimize innovative pipeline, improve innovation quality and efficiency – optimize R&D resource allocation, accelerate development of some high-quality assets (early-stage: EGFR, HER2, etc.; pre-clinical: CD47, TIGIT/PD-L1, etc.) • License-in more high-quality assets through BD – rapidly license-in global high-quality innovative drugs to strongly complement our own innovative pipeline (mAb, bispecific, small molecule, ADC, etc.)

2.1

2020 Review: Products and Pipeline

Biosimilar: Multiple Blockbuster Drugs Have Competitive Advantages in China

汉利康® (rituximab)	汉曲优® (trastuzumab)	汉达远® (adalimumab)	汉贝泰® (bevacizumab)
• Product positioning: become a leader in China's rituximab market • First-mover advantage – First biosimilar in China, first domestic rituximab, 20 months earlier than No.2 • The first & the only rituximab that filed NDA for new indication of rheumatoid arthritis in China (2020.12) • Strong sales team – Fosun Pharma built dedicated sales team with nearly 400 people	• Product positioning: become a leader in China's trastuzumab market • First-mover advantage – first domestic trastuzumab, launched nearly 2 years earlier than peers • First self-developed domestic China and EU approved antibody drug • Strong sales team – self-built team with nearly 400 people	• Product positioning: become a leader in China's adalimumab market • Pricing advantage – current lowest price, greatly improve patient affordability • First domestic adalimumab to have phase 3 clinical data on psoriasis; sNDA for uveitis accepted (2021.01) • Strong sales team – Fosun Pharma had a team with nearly 1,000 people in rheumatology department	• Product positioning: become a strong competitor in China's bevacizumab market • Differentiated clinical data – the only domestic bevacizumab with colorectal cancer clinical data • Huge Combo potential – combo with HLX10 (PD-1) for ns-NSCLC, HCC, etc. • Fully utilize differentiated advantage of wAMD indication, compete effectively in China and global markets, maximize product value

Biosimilar: Global Footprint Covers EU/US Markets and More

Farma de Colombia
- Exclusive licensing and commercial rights of rituximab (HLX01) in Colombia, Peru, Ecuador and Venezuela

Accord
- Exclusive commercial rights of trastuzumab (HLX02) in over 70 countries and regions in Europe, MENA, CIS, USA & Canada

Essex (1061.HK)
- Co-development and exclusive license agreement with Essex for bevacizumab (HLX04) in eye disease indications globally



Biosidus
- Exclusive commercial rights of rituximab (HLX01) in Argentina, Paraguay, Uruguay and Bolivia

Mabxience
- Exclusive commercial rights of HLX02 in Argentina, Uruguay, and Paraguay

Cipla
- Exclusive commercial rights of HLX02 in Australia, New Zealand, Colombia and Malaysia

Jacobson (2633.HK)
- Exclusive commercial rights of trastuzumab (HLX02) in Hong Kong and Macau

Henlius

Biosimilar: Blockbuster Drugs such as 汉利康®, 汉曲优®, 汉达远®

	Product (Reference Drug)	Target	Indications	Pre-Clinical	IND	Ph I	Ph II	Ph III	NDA	Launched	Global Partners
Launched	汉利康® (rituximab)	CD20	Non-hodgkin's Lymphoma / Chronic Lymphocytic Leukemia								FOSUN PHARMA 复星医药, BIOSIDUS, FARMA DE COLOMBIA
Launched	汉曲优® (trastuzumab)(1)	HER2	Breast Cancer / Metastatic Gastric Cancer							First Chinese mAb biosimilar launched in both China and the EU	accord, Cipla, Jacobson, mAbxience
Launched	汉达远® (adalimumab)	TNF-α	Psoriasis / Ankylosing Spondylitis / Rheumatoid Arthritis								万邦医药, FOSUN PHARMA 复星医药成员企业
Near commercialization	HLX01 (rituximab)	CD20	Rheumatoid Arthritis								FOSUN PHARMA 复星医药
Near commercialization	HLX04 (bevacizumab)	VEGF	Metastatic Colorectal Cancer / Non-squamous Non-Small Cell Lung Cancer								
Clinical Stage	HLX05 (cetuximab)(2)	EGFR	Metastatic Colorectal Cancer / Squamous Cell Carcinoma of the Head and Neck								Jingze
Clinical Stage	HLX12 (ramucirumab)	VEGFR 2	Gastric Cancer / Metastatic Non-squamous Non-Small Cell Lung Cancer / Metastatic Carcinoma of the Colon and Rectum								
Clinical Stage	HLX11 (pertuzumab)	HER2	Breast Cancer								
Clinical Stage	HLX14 (denosumab)	RANKL	Osteoporosis								
Clinical Stage	HLX13 (ipilimumab)	CTLA-4	Melanoma / Renal Cell Carcinoma / Metastatic Colorectal Cancer								
Clinical Stage	HLX15 (daratumumab)	CD38	Multiple Myeloma								

Core Products

(1) Approved in the EU in July 2020 (EU brand name: Zercepac®); approved in China in August 2020

(2) Commercialisation rights in China have been granted to Shanghai Jingze

Accelerate Innovation: Significantly Improve Innovation Capability

- Systematically analyze and target major indications
- Explore potential new technology platform and innovative molecules

- Fully organize and prioritize current biosimilars and bio-innovatives, select STAR and NOVA projects to accelerate development



- Build effective and systematic R&D decision-making and project initiation mechanisms, fully implement clinical project PGC(1) and establish preliminary early-stage project R-PGC(2)

- Clinical medicine
- Translational medicine

- Create trans-department collaboration mechanism for “product team”, improve execution and collaboration, accelerate product development

(1) PGC，Portfolio Governance Committee
(2) R-PGC, Research-Portfolio Governance Committee

Henlius

Biosimilar: Differentiate and Maximize PD-1 Launch, Accelerate Development of Other Early-Stage Innovative Assets

- Target multiple indications – lung cancer, liver cancer, gastric cancer, MSI-H etc., seek differentiated competition
- Accelerate launch – plan to file NDAs for MSI-H and sq-NSCLC in 2021
- Pre-launch commercial preparation – formulate differentiated PD-1 market strategy, build PD-1 commercial team
- Accelerate phase 3 clinical trials – sq-NSCLC, SCLC etc.
- Strengthen BD – license-in more high-quality assets to further complement our own innovative pipeline
- Build efficient innovative organization and capability – early-stage R&D + translational medicine + clinical medicine + CMC
- Accelerate development of high-quality innovative assets – aim to achieve 2-3 clinical-stage products each year

Henlius

Bio-Innovative: Led by PD-1, Covering Multiple Innovative Targets

Clinical Stage

Product		Target	Indication	Pre-Clinical	IND	Ph I	Ph II	Ph III	NDA	Launched	Global Partners
HLX10	Mono	PD-1	Microsatellite Instability-High / Deficient Mismatch Repair Solid Tumors					Expected to file NDA in China around late March / early April			KGbio
			Hepatitis B Virus								
	+ Chemo	PD-1	Locally Advanced / Metastatic Esophageal Squamous Cell Carcinoma								
			Squamous Non-Small Cell Lung Cancer								
			Extensive-Stage Small Cell Lung Cancer								
			Neo-adjuvant Gastric Cancer								
	+ HLX04	PD-1 +VEGF	Non-squamous Non-Small Cell Lung Cancer								
			Hepatocellular Carcinoma								
			Metastatic Carcinoma of the Colon and Rectum								
	+ HLX07	PD-1 +EGFR	Squamous cell carcinoma of the head and neck								
HLX07(1)		EGFR	Solid Tumors								
HLX20(2)		PD-L1	Solid Tumors								
HLX22		HER2	Breast Cancer / Gastric Cancer								
HLX55(3)		c-MET	Solid Tumors								
HLX04-O(4)		VEGF	Wet Age-related Macular Degeneration								ESSEX 亿胜
HLX56(5)		DR4	Solid Tumors								
HLX71(6)		S1 Protein of SARS-CoV-2	COVID-19								
HLX70(6)			COVID-19								

Global Multi-centre Clinical Trials

(1) IND obtained in China / the USA
(2) IND obtained in Australia / China
(3) Obtained commercialisation rights in China / Southeast Asia / Mid Asia / South Asia, etc.
(4) IND obtained in Australia / the USA
(5) Obtained commercialisation rights in China
(6) IND obtained in the USA

Henlius

R&D: Total Expenditure Continued to Grow with More on Innovative Drugs







- **Two NDAs filed**
  - HLX04 (bevacizumab)
  - HLX01 (rituximab) - rheumatoid arthritis
- **Initiated three global clinical trials**
  - Completion of enrollment of phase 3 global clinical trial of HLX10+Chemo for squamous non-small cell lung cancer (sq-NSCLC)
  - FPI in Turkey for phase 3 clinical trials of HLX10+ chemo for extensive-stage small cell lung cancer (ES-SCLC);
  - Phase 3 clinical trial of HLX04-O (VEGF) for wAMD in AUS has been approved and will start recently, IND has been approved by FDA
- **Initiated several clinical trials**
  - Initiated five clinical trials: HLX10+HLX04 (VEGF) for solid tumor (enrolment completed); HLX07 (EGFR) for solid tumor (Clinical report completed), HLX11 (pertuzumab) for BC; HLX14 (Denosumab) for osteoporosis; HLX55 (c-Met) for solid tumor
  - Initiated four phase 2 clinal trials: HLX10 (PD-1) +chemo for cervical cancer CC; HLX10 (PD-1) +HLX07 (EGFR) for head & neck squamous cell carcinoma (HNSCC); HLX10(PD-1)+HLX04 (VEGF) for Hepatocellular Carcinoma (HCC) (enrolment completed); HLX10(PD-1)+HLX04 (VEGF) for metastatic colorectal cancer (mCRC)
- **Multiple INDs accepted/approved**
  - Bio-innovative drug: HLX26 (LAG-3) for solid tumor/ lymphoma (accepted); HLX56 (DR4) for solid tumor (approved); HLX70 (neutralizing antibody) and HLX71 (ACE2-Fc recombinant protein) for COVID-19 virus
  - Biosimilar: HLX13 (Ipilimumab) for Melanoma (approved); HLX14 (Denosumab) for osteoporosis (approved); HLX15 (Daratumumab) for MM (approved)

Henlius

2.2

2020 Review: Manufacturing

Capacity: Planning Implemented Steadily, Commercial Capacity Further Increased

Xuhui Base

- Commercial capacity increased from 2,000L in 2019 to current 20,000L
- Support commercial manufacturing for 汉利康® (HLX01, Rituximab), 汉曲优® (HLX02, Trastuzumab), and 汉达远® (HLX03, Adalimumab)
- Received EU GMP certification

Songjiang Base (1)

- Planned capacity of 24,000L
- Started pilot production in 2020Q2
- Prepare for production needs before commercial operation of Songjiang Base (2)

Songjiang Base (2)

- Total planned land use of about 33 acres
- Construction started in June 2019
- Manufacturing buildings' structural roof-sealing completed in August 2020
- Completion, and pilot production expected in 2021

Henlius

Integrated Platform Advantage: Three Manufacturing Bases Will Further Increase Integrated Platform Advantage

- Continue to expand commercial manufacturing bases:
  Xuhui Base
  Songjiang Base (1)
  Songjiang Base (2)
- Manufacturing base and matching quality system obtained China and EU GMP certification
- First to use innovative manufacturing technology:
  Single-use technology
  Continuous production technology



- Quality management system covers whole product cycle
- Benchmarking global highest quality standards with manufacturing base certified by China and EU, lay foundation for global commercialization

Forecast of Henlius capacity



Elaborate layout stage (2020-2022)

- Proper capacity arrangement, pre-match corresponding technology and production line for products, maximize capacity
- Prospective production design and process optimization with the aim to achieve leading total cost
- Explore external CMO possibility

Advantage building stage (2023-2025)

- Successfully and commercially apply innovative technology
- Forecast industry/company's future innovative product type, develop leading technology in advance
- Build domestic leading position with total capacity and technology advantages

Barrier consolidation stage (2025+)

- Continue to optimize process, build industry-wise quality/cost-leading production line
- Assist government improve biologics manufacturing standards, establish made-in-China quality benchmark

Henlius

2.3

2020 Review: Commercial Operation

Commercialization Strategy: Achieve Market Share through Differentiation Based on Ecosystem Empowerment

Build preliminary ecosystem
Assist successful product launch

2020-2022

- 汉曲优®: efficient market access and coverage, optimize HER2+ patient therapy ecosystem
- 汉利康®: fully utilize first-mover advantage to establish and consolidate market-leading position
- 汉达远®: utilize partner's rich experience in rheumatology area, develop RA market, build market-leading position
- HLX04 (bevacizumab) : prepare for VBP in advance, grasp opportunity to become a major competitor
- HLX10 (PD-1): advance fast launch, indication expansion and market access of PD-1, achieve differentiated competition through I/O combo strategy, rapidly gain market share in multiple tumors

Improve ecosystem
Build mature collaboration platform

2023-2024

- Continue to increase and strengthen our own commercial capability, especially access and market promotion competitiveness
- Promote diversified collaboration for doctor-patient ecosystem, strongly expand Henlius ecology with mutual empowerment
- Build external collaboration platform for commercial promotion, fully explore mass market potential
- Integrate resources, maximize value combination and commercial value for different products

Build leading position through platform integration strategy

2025

- Form joint force with upcoming rich pipeline, provide whole disease solution for doctors and patients
- Promote platform strategy, build industry leading position
- Diversified business development model

汉利康® (rituximab)and 汉达远® (adalimumab): Become Market Leaders

汉利康® (rituximab)	汉达远® (adalimumab)
Leader of China Biosimilar	Give every auto-immune disease patient proper and possible treatment

- Become leaders in both core and mass markets
- Fully surpass other rituximab competitors
- Fully explore market potential of rheumatoid arthritis which is the first and the only NDA-filing indication (new drug pathway) in China (accepted by NMPA in Dec. 2020)

- Become a leader in China's adalimumab market
- Build the best commercial team in China's adalimumab market, cover core and mass markets, drive ramp-up of whole rheumatology market
- Fully prepare for biologics volume-based procurement

Henlius

汉曲优® (trastuzumab) – “Not Leaving Any HER2+ Breast Cancer Patient Behind”

Collaboration on Physician Education
- Collaborate with medical societies, facilitate at community level
- Empower innovative academic communication platforms and online activities

Collaboration on Testing & Diagnosis
- Collaborate with biomarker testing companies and pathological centres to improve HER2 testing rate and HER+ rate

Collaboration on Patient Affordability
- Collaborate with insurance companies to improve patients’ affordability

Collaboration on Market Access
- Collaborate with the government to promote the research of biosimilar medical insurance policy and payment standards
- Collaborate with commercial companies to maximize market and hospital access

Collaboration on Big Data
- Collaborate with big data companies to strengthen PMS* capabilities and to complement clinical evidence from Chinese patients

Collaboration on Patient Education
- Collaborate with academic societies and patient groups to reduce HCP/ patients communication cost and increase adherence

Market Access
- Collaborate with academic institutions on biosimilar pricing management research
- Prepare in advance, quickly complete entering provincial and integrated-planning area medical insurance system
- Establish pricing strategy and payment plan that fit mid-/long-term growth

Channel
- Select high-quality distributors and DTP pharmacies, establish efficient business channels
- Establish an optimized pricing system, stabilize product price
- Advocate biosimilars, obtain better bidding/ access outcomes

Marketing
- Create strategic partnership-enabled ecosystem
- International top-quality standards for competitive differentiation
- Build a PhIRDA2 Biosimilar Platform, establish industry leadership

Henlius

HLX10 (PD-1, serplulimab) and HLX04 (bevacizumab): Commercial Strategy

HLX10 – Cornerstone of I/O Combo: all tumor targeting, differentiated competition, ecosystem empowerment, globalization		
Differentiated development, Advance Combo therapy, expand therapeutic area	Launch with excellence Rapidly release market potential	Globalization Further develop overseas markets
• Accelerate expansion of PD-1 indication • Actively advance PD-1 combo therapy • PD-1 + innovative therapy Combo	• Differentiated competition, rapidly increase market share • Rapid access • Strategic partnership, empower pan-tumor ecosystem	• Make data-wise preparation for entering major markets through global multi-center clinical study • Achieve overseas market development through global partnership including registration, access, commercialization

HLX04 – Backbone of anti-VEGF Combo therapy: target mass market, turn VBP threat into opportunity		
Access mass market	Advance market access, prepare for volume-based procurement (VBP)	Explore Combo therapy
• Build mass market team • Enhance platform collaboration with mass market • Rapid deployment for more market share	• Centralize best resources for rapid market access in mass market • Meanwhile fully prepare for VBP and turn threat into opportunity	• Actively explore combo therapy with our own products through real-world data or clinical studies initiated by researchers

2020 Revenue: Ramp-up of 汉利康® and Launch of 汉曲优® Drove Significant Revenue Growth











- **Sales of biosimilars continued to increase**
  - 汉利康® (rituximab) 2,000L bioreactor approved, 500mg approved, FL and CLL indications approved (汉利康® retail price: 1,398RMB/100mg)
  - 汉曲优® (trastuzumab) approved in the EU and China
  - 汉达远® (adalimumab) approved in China

- **BD projects were carried forward in an orderly manner**
  - 汉曲优® (trastuzumab) - Reached exclusive development and commercialization license agreements in 3 South American countries with Mabxience; cooperation with Accord upgraded and added exclusive commercial rights in Canada and the USA;
  - HLX04 (bevacizumab) - Co-development and exclusive license agreement with Essex for bevacizumab (HLX04) in eye disease indications globally
  - HLX35 (4-1BB/EGFR) - Co-development and exclusive license agreement with Binacea for HLX35 (4-1BB/EGFR)
  - TROP2 Ab – Exclusive license agreement with Chiome for antibodies targeting human Trop2

Henlius

3

2021 Outlook

Outlook for 2021

Commercialization

Capitalize on first-entrant advantages and increase the global market coverage of products, continue to commercialize more products

- HLX02汉曲优®: fully advance completion of medical insurance activation and tendering/access; complete 70% hospital coverage of top 1000; strive to become market leader with >50% new patient market share in covered market
- HLX01汉利康®: continue to advance market expansion, fully become market leader
- HLX03汉达远®: complete most of medical insurance activation and tendering/access, and key hospital coverage; fully utilize commercial team's experience in rheumatology area to gain significant market share
- HLX04 (bevacizumab): approval expected in 2021Q4, initiate strategic layout preparation
- HLX01 (rituximab) - rheumatoid arthritis indication: approval expected by the end of 2021 or in the first half of 2022; fully prepare for launch
- HLX10 (PD-1): file NDA for MSI-H in the short term; file NDA for sq-NSCLC in 2021H2

R&D

Rapidly build diversified clinical-stage innovative pipeline through internal R&D and license-in

- Continue to optimize and accelerate the R&D pipeline, improve the decision-making mechanism and working mode, and significantly improve the efficiency of R&D
- HLX10(PD-1) based clinical trial of immuno-oncology combination therapy for indications of squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, extensive stage small cell lung cancer, esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, and squamous cell carcinoma will be further promoted in 2021
- Accelerate expansion of innovative potential targets, antibody-drug conjugates (ADC) products and oncolytic virus products through license-in

Manufacturing

Maintain high quality standards and continue to promote industrialization deployment

- Xuhui Base: maximize production capacity while guaranteeing "Henlius Quality", further promote effective operation, continue to decrease cost; add a pre-filled needle production line
- Songjiang Base (1): complete process validation of 24,000L capacity, pilot workshop completes continuous production
- Songjiang Base (2): initiate trial production and start relevant validation work

Henlius 复宏汉霖

Reliable Quality | **Affordable** Innovation